Instalab

Apple (Mal d 1) IgE Test Blood

Pinpoint whether raw apple is triggering your itchy mouth and throat, when birch-pollen allergy is the likely culprit.

Should you take a Apple (Mal d 1) IgE test?

This test is most useful if any of these apply to you.

Itchy Mouth After Raw Apple
You get tingling, itching, or mild swelling in your mouth or throat after biting into raw apple, and want to know if it's a real allergy.
Living With Birch Pollen Allergy
You already react to birch pollen and want to see whether your immune system has spread the reaction to apple and related raw fruits.
Reacting to Multiple Raw Fruits
You notice oral symptoms with apple, peach, hazelnut, or cherry, and want to map which proteins are driving the pattern.
Considering Allergen Immunotherapy
You're exploring sublingual immunotherapy or oral tolerance approaches and need a confirmed sensitization profile to guide treatment.

About Apple (Mal d 1) IgE

If your lips tingle, your throat itches, or your mouth swells after biting into a raw apple, this test can tell you whether your immune system is reacting to apple's main protein. It is most useful for people who already know they react to birch pollen, because the same antibodies that target birch often cross-react with raw apple.

The reaction usually shows up as oral allergy syndrome, a quick burst of mouth and throat symptoms that fade within minutes. Knowing whether Mal d 1 (the main apple allergen) is driving your reactions helps you separate true allergy from food intolerance and decide how cautious to be with raw fruit.

What This Test Actually Measures

This blood test measures Mal d 1 (the major apple allergen) IgE, an antibody your immune system makes when it has been sensitized to a specific protein in apple. Mal d 1 belongs to a family of plant proteins called PR-10 (pathogenesis-related class 10) that share a similar shape with Bet v 1, the main birch pollen allergen. Because the two look so much alike to your immune system, antibodies built against birch pollen can latch onto raw apple too.

This is a more targeted test than a standard whole-apple allergy panel. Instead of looking at a mixture of apple proteins, it isolates the single protein that drives most cases of birch-related apple allergy. In one study from northern China, Mal d 1 was identified as the major sensitizer in apple-allergic patients and outperformed whole-apple extract IgE for diagnosis.

The Birch-Apple Connection

Apple allergy in adults is rarely a primary food allergy. It is most often a downstream effect of birch pollen allergy. Your immune system learns to recognize Bet v 1 (the birch pollen protein) during pollen seasons, and once it knows that shape, it reacts to similar-looking proteins in raw apple, hazelnut, peach, soy, and other foods. This is called pollen-food allergy syndrome.

In a study of birch-allergic patients in northern China, 96.4% of people with antibodies to Bet v 1 also had antibodies to Mal d 1. The two move closely together. If you know you are birch-sensitized, your odds of also reacting to raw apple are high, and this test can confirm whether your immune system has made that cross-reactive jump.

What Elevated Levels Mean

A positive result indicates your immune system has produced IgE antibodies that recognize Mal d 1. In a northern China cohort, a study-defined diagnostic cutoff showed high sensitivity (caught about 94 out of 100 cases) and reasonable specificity (correctly cleared about 75 out of 100 non-allergic people) for apple allergy. In other words, the test is very good at confirming the diagnosis when symptoms are already suspicious.

Levels do not reliably predict how bad your reaction will be. Most Mal d 1-driven apple reactions stay confined to the mouth and throat, even at higher antibody levels. Heating or cooking the apple usually breaks down Mal d 1 enough that it no longer triggers IgE-mediated reactions, which is why most people with this allergy can still eat applesauce, apple pie, or baked apples without trouble.

What Low or Undetectable Levels Mean

A negative blood test does not always rule out apple allergy. In some symptomatic patients, Mal d 1 IgE was undetectable in serum even though their basophils (immune cells that release histamine during allergic reactions) clearly reacted to Mal d 1 and skin tests were positive. This happens when the antibodies are bound to cells in tissues rather than circulating freely in the blood.

Delayed reactions are another blind spot. About 9% of birch pollen-allergic patients can develop delayed-type apple reactions driven by T-cells (a different arm of the immune system), which this test does not capture. If your blood test is negative but your symptoms are obvious and reproducible, the next step is usually a skin prick test with fresh apple or a basophil activation test, not a repeat of the same blood test.

What This Test Helps You Decide

A clear positive in someone with classic oral symptoms confirms birch-related apple allergy and tells you the raw fruit is the problem, not pesticides or additives. It also flags a high likelihood of cross-reactivity with other PR-10 foods like hazelnut, soy, peach, cherry, and pear. Many people with Mal d 1 sensitization react to several of these foods, often without realizing they share a common protein.

This information also matters if you are considering allergen immunotherapy. In a randomized trial of 60 patients with birch pollen-related apple allergy, four months of sublingual immunotherapy using recombinant Mal d 1 improved apple tolerance and induced IgE-blocking antibodies. Knowing your Mal d 1 status helps you and an allergist decide whether you are a candidate for this kind of treatment.

Tracking Your Trend

A single reading is a snapshot. Your Mal d 1 IgE levels can shift with the seasons, especially around birch pollen season, when antibody levels related to birch and its food cross-reactants tend to rise and then partially fall. If you are testing during or just after a high pollen season, your numbers will likely look different than they would in midwinter.

For most people, a baseline test makes sense when you first suspect apple allergy. If you are starting any kind of allergen immunotherapy or actively trying oral tolerance approaches, retesting at 3 to 6 months can show whether your IgE is changing and whether protective IgG-blocking antibodies are developing. For everyone else, annual or biennial retesting is reasonable if your symptoms shift, since this gives you a long enough window to see real change rather than seasonal noise.

When Results Can Be Misleading

  • Seasonal timing: birch pollen season can transiently raise antibody levels related to apple cross-reactivity. Testing right after pollen season may overstate your baseline.
  • Cell-bound IgE: some people have clear apple symptoms and positive basophil activation but no detectable Mal d 1 IgE in blood. A negative test does not rule out clinically real apple allergy.
  • Delayed reactions: T-cell-driven late reactions (such as eczema flares after cooked apple in atopic dermatitis) do not show up on this test and require atopy patch testing.
  • Asymptomatic sensitization: a positive test in someone with no apple symptoms means your immune system recognizes the protein, but does not by itself mean you will react. Clinical history still drives the diagnosis.
  • Birch pollen immunotherapy: treating your hay fever with birch pollen immunotherapy improves respiratory symptoms but has limited effect on Mal d 1 IgE or apple allergy, so do not expect your apple reactions to resolve as a side effect of allergy shots or drops.

What To Do With An Out-of-Pattern Result

If your result is positive and your symptoms match, the next step is usually to confirm cross-reactivity patterns with related PR-10 components like Bet v 1 (birch), Cor a 1 (hazel), Pru p 1 (peach), and Gly m 4 (soy). This builds a fuller map of which raw plant foods you are likely to react to and helps you avoid trial-and-error elimination.

If your result is positive but you have no symptoms, you are sensitized but not necessarily allergic. The reasonable path is to track whether symptoms emerge and avoid restricting your diet based on the lab number alone. If your result is negative but your symptoms are persistent and reproducible, an allergist can add a skin prick test with fresh apple, a basophil activation test, or a supervised oral challenge to clarify what is happening at the tissue level.

What Moves This Biomarker

Evidence-backed interventions that affect your Apple (Mal d 1) IgE level

↑ Increase
Sublingual immunotherapy with recombinant Mal d 1
This treatment can help your body tolerate raw apple by training your immune system to produce blocking antibodies, even though your Mal d 1 IgE itself often stays the same or rises during therapy. In a randomized trial of 60 patients with birch pollen-related apple allergy, four months of daily sublingual immunotherapy with recombinant Mal d 1 was safe and effective, and a follow-up study confirmed it generated functional IgE-blocking IgG1 antibodies (a protective antibody class) that drove the clinical improvement in the early phase.
MedicationModerate Evidence
↓ Decrease
Daily consumption of selected low-allergen apple cultivars
Eating specific lower-allergen apple varieties daily may gradually reduce reactivity in birch-allergic adults, working as a slow form of oral tolerance. In a study of 52 birch-allergic patients, daily apple consumption with cultivars like Santana and Pink Lady produced the fewest allergic reactions and showed promise as a tolerance-building approach. A separate study of oral Mal d 1 exposure also showed transiently reduced Mal d 1-specific IgE alongside modulated T-cell responses.
DietModest Evidence

Frequently Asked Questions

References

21 studies
  1. Wang X, Chen L, Lan T, Wang H, Wang XFrontiers in Medicine2024
  2. Wagner a, Zielinska-blizniewska H, Wagner WAllergy, Asthma & Immunology Research2018
  3. Nothegger B, Reider N, Covaciu C, Cova V, Ahammer L, Eidelpes R, Unterhauser J, Platzgummer S, Tollinger M, Letschka T, Eisendle KJournal of the European Academy of Dermatology and Venereology2020
  4. Knyziak-medrzycka I, Majsiak E, Gromek W, Kozlowska D, Swadzba J, Bierla J, Kurzawa R, Cukrowska BInternational Journal of Molecular Sciences2024